Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

Breast Cancer Research and Treatment

Volumn 39, Issue 3, 1996, Pages 285-291

  Terenziani, Monica ^a   Demicheli, Romano ^a   Brambilla, Cristina ^a   Ferrari, Laura ^a   Moliterni, Angela ^a   Zambetti, Milvia ^a   Caraceni, Augusto ^a   Martini, Cinzia ^a   Bonadonna, Gianni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPENIA; PAIN; PERIODICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029757636     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806156     Document Type: Article

References (18)

1. Debonis D, Terz JJ, Eldar S et al.: Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol 48: 158-163, 1991
2. Binet S, Fellous A, Lataste H et al.: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16: 5-8, 1989
3. Besenval M, Delgado M, Demarez JP et al.: Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol 16: 37-40, 1989
4. Armand JP, Marty M: Navelbine: a new step in cancer therapy? Semin Oncol 16 (2) Suppl 4: 41-45, 1989
5. Cannobbio L, Boccardo F, Pastorino G et al.: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16 (Suppl 4): 33-36, 1989
6. Extra JM, Leandri S, Dieras V et al.: Phase II study of vinorelbine in first and second line treatment of advanced breast cancer. In: Navelbine Update and New Trends. John Libbey Eurotext LDT (Paris-London): 213-220, 1991
7. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253, 1992
8. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288, 1984
9. Wilkinson, Leland. Systat: the system for statistics. Evanston, IL: Systat, Inc 1988
10. Fumoleau P, Delgado FM, Delozier T et al.: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer. J Clin Oncol 11: 1245-1252, 1993
11. Romero A, Rabinovich MG, Vallejo CT et al.: Vinorelbine as first-line chemotherapy for metastatic carcinoma. J Clin Oncol 12: 336-341, 1994
12. Lluch A, Garcia Conde J, Casado A et al.: Phase II trial with navelbine in advanced breast cancer previously untreated. Proc Am Soc Clin Oncol 11: 72 (Abstr 115), 1992
13. Weber B, Vogel C, Jones L et al.: A U.S. multicenter phase II trial of navelbine in advanced breast cancer. Proc Am Soc Clin Oncol 12: 61 (Abstr 46), 1993
14. Degardin M, Bonneterre J, Hecquet B et al.: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423-426, 1994
15. Gasparini G, Caffo O, Barni S et al.: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12: 2094-2101, 1994
16. Patel NH, Rothenberg ML: Multidrug resistance in cancer chemotherapy. Invest New Drugs 12: 1-13, 1994
17. Mathe G, Ribaud P, Gouveia J: Pierre Fabre Internal Report on Navelbine, part IV B. vol 2/38, 1988
18. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5: 817-820, 1994